Form 4: BioCardia CEO Altman Boosts Stake

BioCardia's President and CEO, Peter Altman, acquired an additional 900 shares of common stock in open market transactions.

Summary

• Peter Altman, President and CEO, and a Director of BioCardia, Inc. (BCDA), acquired additional shares of the company's common stock.
• On January 20, 2026, Altman purchased 600 shares at a weighted average price of $1.32 per share.
• On January 21, 2026, Altman purchased an additional 300 shares at a weighted average price of $1.34 per share.
• These transactions increased Altman's direct beneficial ownership to 268,866 shares of common stock.
• The transactions were made pursuant to a Rule 10b5-1 pre-planned trading arrangement.

Sentiment

Score: 8

Explanation: The insider buying by the CEO, even if pre-planned, generally indicates strong confidence in the company's prospects, which is a positive signal for investors.

Positives

• Insider buying by the President and CEO signals confidence in the company's future prospects.
• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy.

Future Outlook

NA

Industry Context

Insider transactions, particularly by top executives like the CEO, are often viewed by the market as a signal of management's belief in the company's intrinsic value and future performance, regardless of broader industry trends. In the biotechnology sector, such signals can be particularly impactful given the long development cycles and binary outcomes of clinical trials.

Related Party Transactions

• Peter Altman, President and CEO, purchased shares of BioCardia, Inc. common stock.

Stakeholder Impact

• Shareholders may view the CEO's share purchases as a positive indicator of future stock performance and management alignment with shareholder interests.
• Increased investor confidence could potentially lead to positive movement in the company's stock price.

Key Dates

Recommendation

The purchase of company stock by the President and CEO, Peter Altman, signals strong insider confidence in BioCardia's future. While the transactions were pre-planned under Rule 10b5-1, the act of an executive increasing their stake is generally a bullish indicator, suggesting they believe the stock is undervalued or poised for growth. This aligns management's interests more closely with shareholders and could be a catalyst for positive sentiment.

Keywords

BioCardia, BCDA, Peter Altman, Insider Trading, Form 4, Stock Purchase, CEO, Director, Biotechnology, Healthcare